Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
MLP & Energy Infrastructure ETF provides investors with broad exposure to MLP companies operating midstream pipeline assets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback